2023-12-18 18:31:00来源：2024年美国临床肿瘤学会泌尿男生殖系肿瘤分会（ASCO-GU）年会 医脉通阅读：342次
2024年美国临床肿瘤学会泌尿男生殖系肿瘤分会（ASCO-GU）年会将于当地时间2024年1月25日至27日在旧金山盛大召开。ASCO GU是泌尿男生殖系肿瘤领域的学术盛会，会议将展示该领域最具创新性的科学进展，并探讨泌尿男生殖系肿瘤未来的治疗方向。我国专家有多项研究将于本届盛会亮相世界学术舞台，医脉通邀您先睹为快！
Poster Session
壁报专场
前列腺癌
01 摘要号：133
标题：The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
讲者：郭宏骞
单位：南京鼓楼医院
海报号：F4
02 摘要号：146
标题：Efficacy and safety between first-line therapies in metastatic castration-resistant prostate cancer in combination in the PARPi and ARSI era: A systematic review and network meta-analysis.
讲者：Xuanjun Guo
单位：北京大学第一医院
海报号：F17
03 摘要号：167
标题：The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.
讲者：Yifu Shi
单位：四川大学华西医院
海报号：G17
04 摘要号：176
标题：Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67.
讲者：Fengnian Zhao
单位：四川大学华西医院
海报号：H5
05 摘要号：275
标题：Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.
讲者：Haoran Tang
单位：慧渡（上海）医疗科技有限公司
海报号：L10
06 摘要号：321
标题：Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
讲者：庄君龙
单位：南京鼓楼医院
海报号：N12
07 摘要号：327
标题：Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study.
讲者：庄君龙
单位：南京鼓楼医院
海报号：N18
尿路上皮癌
08 摘要号：591
标题：A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC).
讲者：黄吉炜
单位：上海交通大学医学院附属仁济医院
海报号：F18
09 摘要号：593
标题：Blue light cystoscopy versus white light cystoscopy for the detection of bladder cancer in China: An analysis of unpublished clinical trial and real-world data.
讲者：李汉忠
单位：北京协和医院
海报号：F20
10 摘要号：596
标题：Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.
讲者：曾宇
单位：辽宁省肿瘤医院
海报号：G2
11 摘要号：615
标题：Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
讲者：沈益君
单位：复旦大学附属肿瘤医院
海报号：G21
12 摘要号：618
标题：Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
讲者：王宗任
单位：中山大学附属第一医院
海报号：H3
13 摘要号：619
标题：Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study.
讲者：Xiao Yang
单位：南京医科大学第一附属医院
海报号：H4
14 摘要号：622
标题：Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).
讲者：叶定伟
单位：复旦大学附属肿瘤医院
海报号：H7
15 摘要号：623
标题：Performance of the OncoUrine test on predicting patients who can avoid Re-TURBT and prognosis: A prospective, multicenter clinical study.
讲者：Xiao Yang
单位：南京医科大学第一附属医院
海报号：H8
16 摘要号：631
标题：Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer.
讲者：李成龙
单位：武汉大学人民医院
海报号：H16
17 摘要号：636
标题：Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
讲者：毕新刚
单位：中国医学科学院肿瘤医院
海报号：H21
18 摘要号：644
标题：RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.
讲者：Haoyang Liu
单位：四川大学华西医院
海报号：J8
19 摘要号：655
标题：Mutational signature and prognosis in adenocarcinoma of bladder.
讲者：杨国良
单位：上海交通大学医学院附属仁济医院
海报号：J19
20 摘要号：659
标题：Predictive roles of NETs and IgG in neoadjuvant chemotherapy for muscle-invasive bladder cancer.
讲者：Bing-Qing Shang
单位：中国医学科学院肿瘤医院
海报号：K3
21 摘要号：699
标题：The impact and mechanisms of gut microbiota on the efficacy of neoadjuvant therapy in patients with MIBC.
讲者：Tao Li
单位：西安交通大学第一附属医院
海报号：K14
22 摘要号：671
标题：Applying fragmentomics profiles of urinary cell-free DNA for bladder cancer detection.
讲者：Ruiyun Zhang
单位：上海交通大学医学院附属仁济医院
海报号：K15
肾细胞癌；肾上腺癌、阴茎癌和睾丸癌
23 摘要号：420
标题：A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
讲者：张顺
单位：南京鼓楼医院
海报号：H2
24 摘要号：427
标题：Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immunotherapy: A systematic review and meta-analysis.
讲者：Fengnian Zhao
单位：四川大学华西医院
海报号：H9
25 摘要号：429
标题：Outcomes and prognostic factors of first-line combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in TFE3-rearranged renal cell carcinoma.
讲者：Junjie Zhao
单位：四川大学华西医院
海报号：H11
26 摘要号：431
标题：Immune-related adverse events (irAEs) and the association with clinical outcomes in advanced genitourinary cancers treated with immunotherapy: A systematic review and meta-analysis.
讲者：Yaowen Zhang
单位：四川大学华西医院
海报号：H13
27 摘要号：441
标题：Neutrophil extracellular traps in relation to efficacy of systemic therapy for metastatic renal cell carcinoma.
讲者：Rui-Yang Xie
单位：北京大学第三医院
海报号：J2
28 摘要号：442
标题：Serum IgG: A potential biomarker for predicting the efficacy of systemic therapy in metastatic renal cell carcinoma.
讲者：Honglei Cui
单位：中国医学科学院肿瘤医院
海报号：J3
29 摘要号：443
标题：High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma.
讲者：Jie Wu
单位：中国医学科学院肿瘤医院
海报号：J4
30 摘要号：462
标题：Clinicopathological features and transcriptomic profiles of MED15-TFE3-rearranged renal cell carcinoma: A retrospective study of 14 cases.
讲者：Sike He
单位：四川大学华西医院
海报号：K3
31 摘要号：466
标题：The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma.
讲者：Zilin Wang
单位：四川大学华西医院
海报号：K7
32 摘要号：507
标题：A novel radiomics-miRNAs integrated model to predict the histopathology of residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors.
讲者：李向东
单位：中山大学肿瘤防治中心
海报号：L9
Trials in Progress Poster Session
进行中的试验海报专场
33 摘要号：TPS233
标题：Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer.
讲者：王少刚
单位：华中科技大学同济医学院附属同济医院
海报号：P16
34 摘要号：TPS355
标题：Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.
讲者：张顺
单位：南京鼓楼医院
海报号：R7
35 摘要号：TPS718
标题：WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
讲者：鲍一歌
单位：四川大学华西医院
海报号：M18
备注：排名不分先后，按照摘要号进行排序
如有遗漏或任何问题，请给我们留言~